BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA’s emergency use authorization, is now using mRNA to tackle another disease: malaria. The ...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022 BioNTech is evaluating sustainable mRNA vaccine production ...

BERLIN, Dec 23 (Reuters) - BioNTech (22UAy.DE), opens new tab on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said. The Phase 1 ...

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the company's Investigational New Drug application and mid-stage trial evaluating ...

BERLIN, Dec 23 (Reuters) - BioNTech 22UAy.DE has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on ...

Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study. BioNTech SE (BNTX) is running a Phase I/IIa trial called “A Randomized, Dose-escalation Phase I/IIa Trial With ...

Investing.com – BioNTech (NASDAQ:BNTX) stock rose more than 3% Monday following the launch of the company’s ‘Project Malaria’ which aims to develop a vaccine to prevent malaria in Africa. The vaccine ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on BioNTech SE’s (NASDAQ:BNTX) Investigational New Drug application (IND) and the related Phase 1/2a trial evaluating the ...

BioNTech SE has begun human trials on a vaccine for malaria, a fresh test for the messenger RNA technology that powered the most successful immunizations against Covid-19. The first patient was dosed ...

FILE PHOTO: Test tubes are seen in front of a displayed Biontech logo in this illustration BERLIN (Reuters) -BioNTech on Friday initiated an early-stage study to evaluate its experimental malaria ...